About this trial
This study plans to analyze the molecular and clinical mechanisms of the relationship between the GBA mutations and Parkinson's disease. This will be assessed through the use of advanced neuroimaging techniques called PET (positron emission tomography) to study the accumulation of the tau protein and the dysfunction of acetylcholine and dopamine in the brain of people with a mutation in the GBA gene, with and without Parkinson's disease. The ingestigators will also use a technology-based assessment to study the typing patterns as possible biomarkers of early motor dysfunctions.
Eligibility criteria
Qualifiers
heterozygous for a pathogenic GBA mutation (e.g., p.L444P, p.N370S) or polymorphism;
age 18 to 80 years.
Disqualifiers
co-occurrence of other neurological disorders;
implants that contraindicate the MRI scanning (e.g. cardiac pacemaker, ferromagnetic implants or devices);
severe claustrophobia;
intolerance to antiparkinsonian drug withdrawal (for GBA-PD subjects);
Trial design
Treatments tested in this trial
- PET scan
- neuroQWERTY
Treatment groups
Sponsors and collaborators
Pacific Parkinson's Research Centre
Lead sponsor
University of British Columbia
Collaborator
University of Washington
Collaborator
Oregon Health and Science University
Collaborator
Simon Fraser University
Collaborator
Michael J. Fox Foundation for Parkinson's Research
Collaborator
Silverstein Foundation
Collaborator
Weston Brain Institute
Collaborator